Profound Medical Corp. (PROF)
NASDAQ: PROF · IEX Real-Time Price · USD
7.65
+0.03 (0.39%)
May 8, 2024, 1:41 PM EDT - Market open
Profound Medical Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Profound Medical stock have an average target of 12.6, with a low estimate of 9.00 and a high estimate of 18. The average target predicts an increase of 64.71% from the current stock price of 7.65.
Analyst Consensus: Buy
* Price targets were last updated on Mar 11, 2024.
Analyst Ratings
The average analyst rating for PROF stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Alliance Global Partners | Alliance Global Partners | Strong Buy Maintains $13 → $11 | Strong Buy | Maintains | $13 → $11 | +41.18% | Mar 11, 2024 |
| Stifel | Stifel | Hold Maintains $11 → $9 | Hold | Maintains | $11 → $9 | +17.65% | Mar 8, 2024 |
| Alliance Global Partners | Alliance Global Partners | Strong Buy Maintains $14 → $13 | Strong Buy | Maintains | $14 → $13 | +66.67% | Jan 4, 2024 |
| Stifel | Stifel | Hold Initiates $11 | Hold | Initiates | $11 | +43.79% | Nov 28, 2023 |
| Raymond James | Raymond James | Strong Buy → Buy Downgrades n/a | Strong Buy → Buy | Downgrades | n/a | n/a | Aug 4, 2023 |
Financial Forecast
Revenue This Year
12.25M
from 7.20M
Increased by 70.11%
Revenue Next Year
34.59M
from 12.25M
Increased by 182.44%
EPS This Year
-1.06
from -1.35
EPS Next Year
-0.49
from -1.06
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 14.8M | 48.1M | 62.2M | 154.6M | 166.5M |
| Avg | 12.2M | 34.6M | 49.2M | 103.6M | 113.4M |
| Low | 10.3M | 21.6M | 34.2M | 57.6M | 64.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 105.2% | 292.5% | 79.9% | 214.0% | 60.8% |
| Avg | 70.1% | 182.4% | 42.4% | 110.3% | 9.5% |
| Low | 43.0% | 76.1% | -1.1% | 16.9% | -37.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.01 | -0.20 | -0.29 | 1.89 | -0.11 |
| Avg | -1.06 | -0.49 | -0.38 | 1.47 | -0.10 |
| Low | -1.10 | -0.74 | -0.47 | 1.03 | -0.10 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.